- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT02745158
Registr připojení Fibrodysplasia Ossificans Progressiva (FOP).
FOP Connection: Globální registr pro komunitu Fibrodysplasia Ossificans Progressiva
The Fibrodysplasia Ossificans Progressiva (FOP) Registry is a global, non-interventional, voluntary database that captures demographic and disease data directly from FOP patients and their caregivers via a secure, web-based patient portal. A physician portal (in development) will allow physicians to enter clinical data about their patients. The objectives are to organize the international FOP community for participation in clinical trials; to enable FOP patients worldwide to report data in a shared forum; to improve the collective understanding of FOP natural history; and to advance the understanding of FOP treatment outcomes.
Přehled studie
Postavení
Detailní popis
The FOP Registry is a global, non-interventional, voluntary database that captures demographic and disease data directly from FOP patients and their caregivers via a secure, web-based patient portal. No experimental intervention is involved. The objectives are to organize the international FOP community for participation in clinical trials; to enable FOP patients worldwide to report data in a shared forum; to improve the collective understanding of FOP natural history; and to advance the understanding of FOP treatment outcomes.
The Registry collects data through two sources. First, the Patient Portal (launched in July 2015) allows FOP patients and caregivers to enter information about their experiences living with FOP. Second, the Physician Portal (in development) will allow physicians to enter clinical data about patients under their care. The Registry will be capable of including data on specific marketed therapies under the direction and control of a sponsoring pharmaceutical company. Key identifiers will link the physician-reported data with the Patient Portal data.
Participants must have a confirmed diagnosis of FOP and the participant (or a parent or legal guardian) must be willing and able to provide written informed consent. There are no exclusion criteria. Data collected in the Patient Portal include: patient demographics and diagnosis pathway; medical and dental care; clinical research participation and biospecimen donation; heterotopic ossification (bone growth and episodic flare-ups); other signs and symptoms by body system; patient-reported outcomes (physical functioning, pain, fatigue, and general health); and assistive devices, aids, attendants, and adaptations. Because the Registry is designed to accommodate participants along a broad spectrum of FOP disease severity, most of the data fields are optional, allowing participants a high degree of flexibility in how much information they contribute, which also minimizes participant burden.
After completing the informed consent, participants enter their baseline (historical) data. Participants will be encouraged to update their information at least twice per year. Participants may withdraw their consent at any time without prejudice or providing an explanation. The Registry has no pre-specified end date and will continue for as long as it is sustainable and useful to the FOP community.
Typ studie
Zápis (Odhadovaný)
Kontakty a umístění
Studijní kontakt
- Jméno: Sammi Kile, MS
- Telefonní číslo: 1-720-341-6999
- E-mail: registry@ifopa.org
Studijní záloha kontaktů
- Jméno: Mark Hamilton, PhD
- Telefonní číslo: 1-203-605-2122
- E-mail: mark.hamilton@ifopa.org
Studijní místa
-
-
Missouri
-
North Kansas City, Missouri, Spojené státy, 064116
- Nábor
- The International Fibrodysplasia Ossificans Progressiva Association (IFOPA)
-
Kontakt:
- Sammi Kile, MS
- Telefonní číslo: 1-720-341-6999
- E-mail: registry@ifopa.org
-
Kontakt:
- Mark Hamilton, PhD
- Telefonní číslo: 1-203-605=2122
- E-mail: mark.hamilton@ifopa.org
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
- Dítě
- Dospělý
- Starší dospělý
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Metoda odběru vzorků
Studijní populace
Individuals with Fibrodysplasia Ossificans Progressive (FOP) from the international FOP community will be invited to join the Registry.
Popis
Inclusion Criteria:
- Participants must have a confirmed diagnosis of FOP.
- Participants (or a parent or legal guardian) must be willing and able to provide written informed consent.
Exclusion Criteria:
- There are no exclusion criteria.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Observační modely: OTHER
- Časové perspektivy: PROSPECTIVE
Kohorty a intervence
Skupina / kohorta |
|---|
|
FOP Patients
None. IFOPA-REG-001 is a FOP patient observational registry study. |
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Patient Reported Changes in New Bone Growth Using a Patient-Directed Survey Developed by the IFOPA
Časové okno: Baseline, then every six months for up to 10 years
|
The patient is able to report changes in new bone growth among 27 joints and body locations. |
Baseline, then every six months for up to 10 years
|
|
Patient Reported Changes in Episodic Flare-Ups Using a Patient-Directed Survey Developed by the IFOPA
Časové okno: Baseline, then every six months for up to 10 years
|
The patient is able to report changes in episodic flare-ups among 27 joints and body locations. |
Baseline, then every six months for up to 10 years
|
|
Patient Reported Changes in Mobility Using a Patient-Directed Survey Developed by the IFOPA
Časové okno: Baseline, then every six months for up to 10 years
|
The patient is able to report changes in mobility among 27 joints and body locations. |
Baseline, then every six months for up to 10 years
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Patient Reported Changes in Health Resource Utilization Using a Patient-Directed Survey Developed by the IFOPA
Časové okno: Baseline, then every six months for up to 10 years
|
The number of visits to a Physician and a Dentist, as well as the number of hospitalizations and reasons for the hospitalizations, are used to assess health resource utilization. |
Baseline, then every six months for up to 10 years
|
|
Patient Reported Changes in Signs Related to the Ear Using a Patient-Directed Survey Developed by the IFOPA
Časové okno: Baseline, then every six months for up to 10 years
|
The patient is able to report new or continuing health issues related to the ears. |
Baseline, then every six months for up to 10 years
|
|
Patient Reported Changes in Signs Related to the Skin Using a Patient-Directed Survey Developed by the IFOPA
Časové okno: Baseline, then every six months for up to 10 years
|
The patient is able to report new or continuing health issues related to the skin. |
Baseline, then every six months for up to 10 years
|
|
Patient Reported Changes in Signs Related to the Central Nervous System Using a Patient-Directed Survey Developed by the IFOPA
Časové okno: Baseline, then every six months for up to 10 years
|
The patient is able to report new or continuing health issues related to the central nervous system. |
Baseline, then every six months for up to 10 years
|
|
Patient Reported Changes in Signs Related to the Pulmonary System Using a Patient-Directed Survey Developed by the IFOPA
Časové okno: Baseline, then every six months for up to 10 years
|
The patient is able to report new or continuing health issues related to the pulmonary system. |
Baseline, then every six months for up to 10 years
|
|
Patient Reported Changes in Signs Related to the Gastrointestinal System Using a Patient-Directed Survey Developed by the IFOPA
Časové okno: Baseline, then every six months for up to 10 years
|
The patient is able to report new or continuing health issues related to the gastrointestinal system. |
Baseline, then every six months for up to 10 years
|
|
Patient Reported Changes in Signs Related to the Cardiovascular System Using a Patient-Directed Survey Developed by the IFOPA
Časové okno: Baseline, then every six months for up to 10 years
|
The patient is able to report new or continuing health issues related to the cardiovascular system. |
Baseline, then every six months for up to 10 years
|
|
Patient Reported Changes in Signs Related to the Renal System Using a Patient-Directed Survey Developed by the IFOPA
Časové okno: Baseline, then every six months for up to 10 years
|
The patient is able to report new or continuing health issues related to the renal system. |
Baseline, then every six months for up to 10 years
|
|
Patient Reported Changes in Signs Related to the Endocrine System Using a Patient-Directed Survey Developed by the IFOPA
Časové okno: Baseline, then every six months for up to 10 years
|
The patient is able to report new or continuing health issues related to the endocrine system. |
Baseline, then every six months for up to 10 years
|
Další výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Pacientem hlášené změny v aktivitách každodenního života pomocí FOP-Physical Functioning Questionnaire (PFQ)
Časové okno: Základní stav, poté každých šest měsíců po dobu až 10 let
|
Základní stav, poté každých šest měsíců po dobu až 10 let
|
|
|
Pacient hlásil změny v celkovém zdraví pomocí Globální škály zdraví PROMIS
Časové okno: Základní stav, poté každých šest měsíců po dobu až 10 let
|
Základní stav, poté každých šest měsíců po dobu až 10 let
|
|
|
Patient Reported Changes in the Need for Assistive Devices, Aids, Attendants, and Adaptations Using a Survey Developed by the IFOPA
Časové okno: Baseline, then every six months for up to 10 years
|
The patient is able to respond Yes or No to questions related to his/her need for Assistive Devices, Aids, Attendants, and Adaptations as a result of his/her FOP disease. |
Baseline, then every six months for up to 10 years
|
Spolupracovníci a vyšetřovatelé
Vyšetřovatelé
- Ředitel studie: Mark Hamilton, PhD, International Fibrodysplasia Ossificans Progressiva Association
Publikace a užitečné odkazy
Užitečné odkazy
- <p>Click here for more information about this study: The FOP Connection Registry</p>
- <p>The International FOP Association is a 501(c)(3) non-profit organization supporting medical research, education and communication for those afflicted by the rare genetic condition Fibrodysplasia Ossificans Progressiva (FOP).</p>
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Odhadovaný)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Odhadovaný)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
- Přírodní historie
- Mobilita
- Výsledky hlášené pacientem
- Hallux Valgus
- Registr pacientů
- Kloub
- FOP
- Fibrodysplasia ossificans progressiva
- Mezinárodní asociace FOP
- Skupina pro advokacii pacientů
- Observační databáze
- Kostní morfogenetický protein
- BMP
- Růst kostí
- Vzplanutí
- Heterotopická osifikace
- Ektopická kost
- Osteochondrom
- ALK2
- ACVR1
- Aktivin A
- IFOPA
- Receptor aktivinu A typu I
- Kináza-2 podobná receptoru aktivinu
Další relevantní podmínky MeSH
- Nemoci kostí
- Nemoci pohybového aparátu
- Svalová onemocnění
- Patologické procesy
- Novotvary
- Novotvary podle histologického typu
- Novotvary, pojivové a měkké tkáně
- Novotvary, kostní tkáň
- Novotvary, pojivová tkáň
- Osteochondrodysplazie
- Nemoci kostí, vývojové
- Myositida
- Deformace chodidla
- Patologické stavy, příznaky a symptomy
- Osteochondrom
- Myositis Ossificans
- Hallux Valgus
- Osifikace, heterotopická
Další identifikační čísla studie
- IFOPA-REG-001
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Popis plánu IPD
Formal data sharing agreements are planned between the International FOP Association and biopharmaceutical companies doing research in Fibrodysplasia Ossificans Progressiva (FOP). Publications are also planned with biopharmaceutical companies and physician researchers.
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .